摘要:
A novel α-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; R 1 is the same or different, and represents a halogen atom, or a C 1 -C 3 alkyl group; R 2 represents a hydrogen atom, or a C 1 -C 6 alkyl group; p represents an integer of 0 to 5; V represents CR 3 wherein R 3 represents a hydrogen atom, an amino group, a nitro group, or a C 1 -C 3 alkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.
摘要:
Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof:
wherein L 1 is an optionally substituted C 1-6 alkylene group or the like, L 2 is a single bond or the like, L 3 is a single bond or the like, R 1 , R 2 , and R 3 are each independently an optionally substituted C 1-4 alkyl group or the like, R 4 is a hydrogen atom or the like, and R 5 is a hydrogen atom or the like.
摘要:
The present invention provides a salt of a substituted pyridine compound which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a salt of a compound represented by general formula (I):
wherein R 1 is optionally substituted alkoxy or the like.
摘要:
A novel ±-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; R 1 is the same or different, and represents a halogen atom, or a C 1 -C 3 alkyl group; R 2 represents a hydrogen atom, or a C 1 -C 6 alkyl group; p represents an integer of 0 to 5; V represents CR 3 wherein R 3 represents a hydrogen atom, an amino group, a nitro group, or a C 1 -C 3 alkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.
摘要:
Provided is a pharmaceutical composition containing, as an active ingredient thereof, a substituted biaryl compound represented by general formula (I), wherein, R 1 , W, R 2 and Z are as defined in the claims and description, or a pharmacologically acceptable salt thereof. The pharmaceutical composition of the present invention is useful as a therapeutic drug and/or prophylactic drug for chronic obstructive pulmonary disease due to having an excellent anti-inflammatory effect.
摘要:
Disclosed is a pyrrolopyridazinone compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof. (1) In the formula, R1 represents an alkyl group or the like; R2 represents a cycloalkyl group or the like; R3 represents a hydrogen atom or the like; and R4 represents a hydrogen atom, a halogen atom or the like.
摘要:
The present invention discloses a pyrrolopyridazinone compound represented by the formula (1):
wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group -O-R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), "C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group", an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or "C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group", Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl) C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.